We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Cardiology

Zalunfiban at First Medical Contact for STEMI: Faster Coronary Patency and Better 30‑Day Outcomes but More Minor Bleeding

MedXY Editorial Team•Nov 13, 2025•Cardiology
STEMI

Highlights

– Zalunfiban, a subcutaneous glycoprotein IIb/IIIa (αIIbβ3) inhibitor given at first medical contact, improved a 30‑day hierarchical clinical composite in patients with ST‑elevation myocardial infarction (STEMI).

– Zalunfiban accelerated preintervention coronary patency (improved corrected frame count) and lowered the chance of worse outcomes in a multicomponent ranking model (adjusted odds ratio 0.79; 95% CI 0.65–0.98; P=0.028).

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Bivalirudin Versus Heparin in Primary PCI for STEMI: Efficacy Across Low and High Bleeding Risk Patients – Insights from the BRIGHT-4 TrialThe BRIGHT-4 trial demonstrates that bivalirudin with prolonged infusion reduces 30-day mortality and major bleeding compared to heparin in STEMI patients undergoing radial primary PCI, benefiting both low and higher bleeding risk groups.Sep 17, 2026Intravenous Nicorandil in STEMI Patients Undergoing Primary PCI: Insights from the CLEAN Randomized Clinical Trial and Broader EvidenceThe CLEAN trial shows intravenous nicorandil adjunctive to primary PCI does not significantly improve 12-month clinical outcomes in STEMI. Evidence suggests microvascular benefits but no consistent long-term mortality or infarct size reductAug 17, 2026STEMI and NSTEMI Are Not the Same in Type 1 Diabetes: Finnish Cohort Reveals Distinct Risk PatternsIn Finnish adults with type 1 diabetes, STEMI and NSTEMI showed distinct incidence trends and risk profiles. NSTEMI was more common overall and linked to dyslipidemia and advanced microvascular disease, whereas impaired eGFR tracked more wiApr 1, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Minutes Matter: How Modern Medicine is Winning the Race Against Heart Attacks
An extensive study of 575,247 patients reveals significant improvements in hospital response times for heart attacks over the last decade, yet highlights critical gaps in care for women, elderly patients, and those admitted during off-hours
Feb 8, 2026
Ticagrelor vs. Twice-Daily Clopidogrel in STEMI: Insights from the TADCLOT TrialThe TADCLOT trial compared ticagrelor to twice-daily clopidogrel in 2,201 STEMI patients post-PCI. While ticagrelor showed no 30-day superiority in MACE reduction, it demonstrated a significant benefit within the first two weeks with comparJan 17, 2026
Mental Health Labels Linked to Critical Delays and Doubled Five-Year Mortality in STEMI CareA prospective study reveals that patients with mental health conditions face significant delays in STEMI diagnosis, resulting in larger infarct sizes and a twofold increase in five-year cardiovascular mortality compared to those without sucJan 3, 2026